Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralipid for recurrent implantation failure in frozen embryo transfer cycles
IRCT20220725055555N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Aug 2022
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Intralipid 10% in Recurrent Implantation Failure (RIF) and infertility (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Chemical pregnancy rate, Clinical pregnancy rate and 3 more. Started Aug 2022; status: completed.
02
Drugs
Intralipid 10%
03
Conditions
Recurrent Implantation Failure (RIF)infertility
Beyond the preview
Go deeper on IRCT20220725055555N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220725055555N1.